MiniMed Group, Inc.

NasdaqGS:MMED Stock Report

Market Cap: US$4.1b

MiniMed Group Management

Management criteria checks 1/4

MiniMed Group's CEO is Que Dallara, appointed in Mar 2026, has a tenure of less than a year. total yearly compensation is $8.46M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.002% of the company’s shares, worth $97.42K. The average tenure of the management team and the board of directors is 0.3 years and 0.3 years respectively.

Key information

Que Dallara

Chief executive officer

US$8.5m

Total compensation

CEO salary percentage8.96%
CEO tenureless than a year
CEO ownership0.002%
Management average tenureless than a year
Board average tenureless than a year

Recent management updates

No updates

Recent updates

Seeking Alpha Jun 02

MiniMed: Waiting For The First Earnings Report

Summary MiniMed Group, recently spun out from Medtronic, is a global insulin pump and CGM provider with $2.7B FY25 revenue but remains unprofitable. MMED trades at a price/sales ratio near 1 after a 45% post-IPO decline, suggesting potential undervaluation if profitability is achieved. Growth prospects are supported by expanding diabetes prevalence and robust market CAGRs for insulin delivery and CGM devices. I rate MMED a 'Hold' pending the June 3, 2026, earnings release, which should clarify its path to profitability and intrinsic value. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Que Dallara's remuneration changed compared to MiniMed Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Apr 24 2026n/an/a

-US$331m

Jan 23 2026n/an/a

-US$320m

Oct 24 2025n/an/a

-US$211m

Jul 24 2025n/an/a

-US$212m

Apr 25 2025US$8mUS$758k

-US$213m

Compensation vs Market: Que's total compensation ($USD8.46M) is about average for companies of similar size in the US market ($USD6.92M).

Compensation vs Earnings: Insufficient data to compare Que's compensation with company performance.


CEO

Que Dallara (52 yo)

less than a year
Tenure
US$8,458,163
Compensation

Ms. Que Thanh Dallara serves as CEO & Director of Minimed Group, Inc. since March 6, 2026. Ms. Dallara served as Executive Vice President and President Diabetes Operating Unit at Medtronic plc and Medtroni...


Leadership Team

NamePositionTenureCompensationOwnership
Que Dallara
CEO & Directorless than a yearUS$8.46m0.0024%
$ 97.4k
Ali Dianaty
Executive VP and Chief Product & Technology Officerless than a yearUS$2.45mno data
Courtney Nelson Wills
SVP, General Counsel & Corporate Secretaryless than a yearUS$1.21mno data
Gillian Chandrasena
Senior VP & Chief Human Resources Officerless than a yearUS$1.84mno data
Christopher Eso
Presidentno datano datano data
Chad Spooner
Executive VP & CFOless than a yearno datano data
John Gyurci
VP, Chief Accounting Officer & Controllerless than a yearno datano data
Mike Bruggeman
SVP & Chief Information Officerno datano datano data
Ryan Weispfenning
Head of Investor Relationsless than a yearno datano data
Kate Cronin
SVP & Chief Marketing Officerno datano datano data
Yael Glassman
SVP, Chief Strategy & Corporate Development Officerno datano datano data
Slobodan Radumilo
SVP & Chief Commercial Officer of EMEA and APACno datano datano data
0.3yrs
Average Tenure
53yo
Average Age

Experienced Management: MMED's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Que Dallara
CEO & Directorless than a yearUS$8.46m0.0024%
$ 97.4k
D. Grossman
Independent Directorless than a yearno datano data
Glenn Eisenberg
Independent Directorless than a yearno datano data
Timothy Wicks
Independent Directorless than a yearno datano data
Kevin Lofton
Independent Chair of Boardless than a yearno datano data
Robert Hopkins
Directorless than a yearno datano data
Brett Wall
Directorless than a yearno datano data
Laura Mauri
Directorless than a yearno datano data
Matthew Walter
Directorless than a yearno datano data
0.3yrs
Average Tenure
60yo
Average Age

Experienced Board: MMED's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/17 18:59
End of Day Share Price 2026/06/17 00:00
Earnings2026/04/24
Annual Earnings2026/04/24

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MiniMed Group, Inc. is covered by 15 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew MiksicBarclays
Bruce JacksonBenchmark Company
Travis SteedBofA Global Research